Table 1.
Classification | Nanocarriers | Nanocarriers properties | Disadvantage |
Organic nanocarriers | Liposomes | (a) Amphiphilic, biocompatible(b) Wide adaptability(c) Targeting potential(d) Ease of modification | (a) Poor stability, easy to be affected by metal radiation, high temperature, pH, and enzymes(b) Low drug loading rate |
Polymeric micelles | (a) Long retention time in the body(b) Suitable carrier for water-insoluble drug(c) Ease of functional modification(d) Biocompatible, self-assembling, biodegradable(e) Special “core-shell” structure, targeting potential | Poor physical stability, resulting in drug leakage and sudden release | |
Polymeric nanoparticles | (a) Water-soluble, nontoxic, and biodegradability(b) High drug loading(c) Selective accumulation and retention in tumor tissue (EPR effect)(d) Active targeting and smart response | (a) Easy binding to negatively charged non-specific cells or proteins(b) Low gene transfection efficiency | |
DNA/RNA | (a) Easy synthesis and modification(b) Low immunogenicity(c) Excellent specificity and affinity(d) Active targeting and Intelligent drug release | (a) Poor cellular uptake(b) Poor stability | |
HSA | (a) Safety, no immunogenicity, good biocompatibility(b) Biodegradable(c) Passive targeting | (a) Large particle size and easy degradation(b) Preparation method is easy to cause increased toxicity(c) Limited sources of HSA | |
Inorganic nanocarriers | Metal nanoparticles | (a) Biocompatible(b) Easy preparation | (a) Need surface modification(b) Poor biocompatibility |
Non-metallic nanoparticles | (a) Low surface potential(b) Low drug loading(c) Easy aggregation |
EPR: Enhanced permeability and retention; HSA: human serum albumin.